1995年，安利在广州黄埔建成第一家工厂，正式开启中国之旅。30年过去，当年的黄土地已发展为占地14.1万平方米的现代化生产基地，支撑着安利全球 55%的产品供应，服务超过50个国家和地区，是安利全球供应链的重要枢纽。 "我当时在这个生产线上时，装箱的环节需要6个人一起，但现在已经不需要了。"站在广州黄埔的安利工厂里，生产主管张章擎指着流畅运转的自动化设备 对来访的记者介绍变化，他当时在生产线上还需要人工的环节，逐渐都实现了自动化。 行走在工厂的车间，透过透明玻璃，随处可见的是各类自动化的机械臂和设备，传送带上的产品在各个站点完成智能分装、自动装盒、自动打包、激光打 码、X射线检测……这些流水线工作都被机器接管，严谨、精确、可视化。 安利投资中国的30年，是扎根与共生的30年。在安利（中国）三十周年庆典上，安利（中国）总裁余放介绍，30年来，安利已陆续在广州、上海和无锡设立 研发中心，从最初的"搬运工—copy美国总部产品"，到现在，"中国市场已经成为全球创新中心"。 这一路径映射出一家跨国企业在中国市场的深度融入与价 值重构。 "投资中国就是投资未来。"安利全球总裁兼首席执行官迈克尔·尼尔森表示，中国已连续 ...

Core Viewpoint - Amway has evolved over 30 years in China, transforming from a foreign entity into a significant local innovator, contributing to the health and wellness sector through localized research and development [1][2]. Group 1: Innovation and Research - Amway has established the largest plant variety resource library in the industry, with over 200 plant species and more than 900 varieties, including 304 varieties of lotus and 131 varieties of blueberries [5]. - The company collaborates with prestigious institutions like the Chinese Academy of Traditional Chinese Medicine and the Nanjing Institute of Soil Sciences, achieving breakthroughs in plant nutrition research [5]. - Amway's plant research center has successfully sequenced the entire genome of chrysanthemum, filling an international gap, and has been awarded for pioneering the application of plant DNA molecular identification technology [5][7]. Group 2: Localized Production and Supply Chain - Amway operates over 2,500 hectares of owned farms in the U.S., Mexico, and Brazil, and has 134 certified organic farms globally, focusing on sustainable plant cultivation [8]. - The company plans to invest in its first organic farm in China, located in Sichuan, which will focus on the cultivation of traditional Chinese medicinal herbs [8]. - The Guangzhou production base supports 55% of Amway's global product sales and serves over 50 countries, becoming a crucial hub in Amway's global supply chain [15]. Group 3: Product Innovation and Market Strategy - Amway has transitioned from "follow-up localization" to "leading localization," launching several successful products based on traditional Chinese medicine that have gained international acclaim [14]. - The company has introduced several flagship products, such as Ginkgo Biloba and various health supplements, achieving significant sales milestones, including over 20 billion yuan in sales for "基源欣活" within two years [15]. - Amway's strategy has shifted towards providing comprehensive health solutions, integrating digital tools and community engagement to enhance customer experience and partner involvement [21][22]. Group 4: Future Investments and Growth - Amway announced a five-year investment plan of 2.1 billion yuan to enhance its operations in China, including 700 million yuan for upgrading the Guangzhou production base and 400 million yuan for digital infrastructure [24]. - The company aims to strengthen its research capabilities, including the establishment of its organic farm and advancements in plant anti-aging research [24]. - Amway's commitment to the Chinese market is reflected in its role as a "city partner" in Guangzhou, focusing on health promotion and community building [22].

Core Viewpoint - Amway (China) celebrates its 30th anniversary and the opening of the "Amway Beautiful Life Plaza" in Guangzhou, marking a significant milestone in its development in China [2][21]. Group 1: Innovation and Research - Amway has established the largest plant variety resource library in the industry, with over 200 types and 900 varieties of plants, including 304 varieties of lotus and 131 varieties of blueberries [5]. - The company collaborates with prestigious institutions like the Chinese Academy of Traditional Chinese Medicine and the Nanjing Institute of Soil Sciences, achieving breakthroughs in plant nutrition research [5]. - Amway's plant research center has completed the whole genome sequencing of chrysanthemum, filling an international gap, and has been awarded the "International Contribution Award for Traditional Chinese Medicine" for its pioneering work in plant DNA molecular identification technology [5]. Group 2: Sustainable Agriculture and Localized Production - Amway is investing in a new organic farm in Sichuan, China, which will focus on the cultivation of traditional Chinese medicinal herbs and aims to enhance the quality and safety of its product raw materials [6]. - The company operates over 2,500 hectares of its own farms in the U.S., Mexico, and Brazil, and has 134 certified organic farms globally, emphasizing organic and sustainable planting methods [6]. Group 3: Market Strategy and Product Development - Amway has transitioned from "follow-up localization" to "leading localization," establishing China as a key market and innovation engine, with localized product development and production [11]. - The company has launched several successful products based on traditional Chinese medicine, such as Ginkgo Biloba tablets, which have generated over $3 billion in sales globally [12]. - Amway's Guangzhou production base supports 55% of its global product sales and serves over 50 countries, becoming a crucial hub in its global supply chain [12][14]. Group 4: Investment and Future Plans - Amway announced a five-year investment plan of 2.1 billion RMB, which includes 700 million RMB for upgrading its Guangzhou production base and 400 million RMB for enhancing digital infrastructure [21]. - The investment also allocates 500 million RMB for research and development, including projects on organic farm construction and plant anti-aging research [21]. Group 5: Community Engagement and Social Responsibility - Amway is recognized as a "strategic partner" in Guangzhou's "City Partner" initiative, focusing on health promotion, ecological friendliness, and community building [19]. - The company aims to integrate its resources with community efforts to create a vibrant and warm urban environment, reflecting its commitment to social responsibility [19][23].

Core Viewpoint - Amway (China) celebrates its 30th anniversary and the opening of the "Amway Beautiful Life Square" in Guangzhou, marking a significant milestone in its development and commitment to the local community [1][2]. Group 1: Investment and Development - Amway has initiated a five-year investment plan totaling 2.1 billion RMB, with allocations for upgrading its Guangzhou production base, enhancing digital infrastructure, and expanding its experience centers across China [2][8]. - The investment includes 700 million RMB for upgrading the Guangzhou production base, 400 million RMB for digital infrastructure, and 500 million RMB for enhancing over 100 experience centers [8]. Group 2: Community Engagement and Health Initiatives - The "Amway Beautiful Life Square" serves as a vibrant outdoor space promoting health and wellness, featuring facilities like the Amway Dock and fitness trails [2]. - Amway actively participates in community initiatives, including the "2025 Guangzhou International Sports Carnival" and the establishment of a volunteer service park, demonstrating its commitment to public health and community support [5]. Group 3: Strategic Partnerships and Urban Development - Amway has been recognized as a "Strategic Partner" in Guangzhou's "City Partner" initiative, focusing on health industry development and enhancing the quality of life for residents [3]. - The partnership aims to promote a healthy ecosystem in Guangzhou, aligning with national strategies such as "Healthy China" and "Beautiful Life" [3][11]. Group 4: Innovation and R&D - Amway has established a localized R&D system in China, with a new research center and health-sharing laboratory aimed at fostering innovation and collaboration in the health sector [12]. - The company has developed a significant plant variety resource library and has engaged in partnerships with leading Chinese research institutions to advance its product development [13]. Group 5: Long-term Commitment to China - Amway views China as a market of immense potential, having consistently increased its investment even during challenging times, such as post-SARS and post-pandemic [8][17]. - The company emphasizes its long-term commitment to the Chinese market, focusing on sustainable practices and contributing to the country's economic development [16][17].

Core Insights - The article highlights the significant growth and transformation of multinational pharmaceutical companies in China over the past eight years, particularly through their participation in the China International Import Expo (CIIE) [11] - Companies like Roche and Gilead are expanding their product offerings and localizing their operations, indicating a shift towards more comprehensive engagement in the Chinese market [3][5] Group 1: Roche's Expansion - Roche has evolved from showcasing a few oncology drugs at the first CIIE to presenting over 40 products and solutions this year, covering the entire industry chain from early research to localized production [3] - The company has launched nearly 15 products in China over the past eight years, with a new biopharmaceutical base in Shanghai aimed at producing large molecule antibody drugs locally [3][5] Group 2: Gilead's Innovations - Gilead is actively advancing local research and development, currently conducting 16 projects in China, including 10 in oncology, with 90% of these projects synchronized with global timelines [5] - The company introduced Lenacapavir, the first long-acting HIV prevention drug requiring only two doses per year, marking a significant milestone in HIV prevention [2][5] Group 3: AstraZeneca's Investments - AstraZeneca signed a $136 million investment agreement for its Qingdao base during the expo, emphasizing China's role as its second-largest market and a source of innovation [3] - The company has invested over $1.7 billion in projects driven by previous CIIE events, embedding its production supply chain deeply into the Chinese market [3] Group 4: Merck and Eli Lilly's Contributions - Merck showcased its first HIF-2α inhibitor for VHL syndrome patients and announced plans to introduce over 40 new products and indications in the next five years [5] - Eli Lilly has invested over 20 billion RMB in China, establishing a comprehensive industry chain from research to commercialization, and plans to continue expanding its local collaborations [5][10] Group 5: Amway's Local Innovations - Amway introduced a vitamin and mineral powder product, the first "blue hat" multivitamin in China, reflecting its commitment to local research and development [6][10] - The company has established a plant research center in Wuxi and is integrating AI and traditional Chinese medicine to enhance its product offerings [8][10] Group 6: The Broader Impact of CIIE - The CIIE has become a platform for global companies to redefine their roles in China, with many establishing local R&D centers and committing to long-term investments [10][11] - The event is seen as a bridge for innovation and trust between China and the world, showcasing the potential for Chinese-developed products to reach global markets [11][12]